RNA-mediated phenotype modulation (RPM) is the first major innovation in skincare active ingredients of this millennium. The action of RPM follows biologic pathways in the skin in addition to more familiar chemical mechanisms, and achieves its results without altering the physiology of the epidermis. The Company believes its active ingredients will not be regulated by the FDA.

As a startup company, the immediate goals of miRcutis are, first, complete the validation phase for its first active ingredient; second, begin the development of the second and third active ingredients, resulting in an intellectual property portfolio encompassing each of the Company’s three skincare focus areas; and third, promote the commercialization of its core RPM technology through collaborations, to integrate RPM into a novel product architecture for the topical treatment of aging, damaged and visually impaired skin.

miRcutis’s development program is sequenced as the discovery and validation of critical microRNAs followed by the identification and testing of substances which tune microRNA expression in the epidermal skin cell. These small molecule modulators can then be used in a variety of conventional product development pipelines familiar to the skincare industry. The Company also intends to explore other innovative mechanisms for the delivery of microRNA active ingredients in novel configurations in the skin. Both programs will be assessed to determine the conditions for rapid scalability as an independent brand of gene expression based skincare and cosmetics products.